Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 11/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15284566 | 1.00 | SLC5A2 (0.59) | SLC5A2EPHX2PYGL | |
| SCHEMBL6542524 | 1.00 | SLC5A2 (0.59) | SLC5A2EPHX2PYGL | |
| SCHEMBL28445368 | 1.00 | SLC5A2 (0.59) | SLC5A2EPHX2PYGL | |
| SCHEMBL15271703 | 1.00 | SLC5A2 (0.59) | SLC5A2EPHX2PYGL | |
| SCHEMBL28433449 | 1.00 | SLC5A2 (0.59) | SLC5A2EPHX2PYGL | |
| SCHEMBL2917657 | 0.98 | SLC5A2 (0.57) | SLC5A2EPHX2PYGL | |
| SCHEMBL15284629 | 0.84 | SLC5A2 (0.48) | SLC5A2EPHX2 | |
| SCHEMBL17941667 | 0.82 | SLC5A2 (0.62) | SLC5A2 | |
| SCHEMBL17941664 | 0.82 | SLC5A2 (0.62) | SLC5A2 | |
| SCHEMBL6673371 | 0.80 | SLC5A2 (0.50) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421385-B1 | GENETIC CONSTRUCT INTRACELLULAR MONITORING SYSTEM | DISCOVERX CORP (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-1766397-B1 | ANALYSIS OF INTRACELLULAR MODIFICATIONS | DISCOVERX CORP (US) | 2016-03-09 | — | — | EP | disclosed |
| US-8101373-B2 | β-galactosidase donor fragments | DISCOVERX CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-7608415-B2 | Analysis of intracellular modifications | DISCOVERX CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090098588-A1 | BETA GALACTOSIDASE DONOR FRAGMENTS | DISCOVERX CORPORATION (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1766397-A4 | ANALYSIS OF INTRACELLULAR MODIFICATIONS | DISCOVERX INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7479377-B2 | Genetic construct intracellular monitoring system | DISCOVERX CORPORATION (US) | 2009-01-20 | — | — | US | disclosed |
| EP-1474526-B1 | ENZYME ACTIVATION PROTEASE ASSAY | DISCOVERX INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7256011-B2 | Enzyme activation protease assay | DISCOVERX INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7202043-B2 | Detecting cell membrane protein endocytosis | DISCOVER CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006004936-A2 | ANALYSIS OF INTRACELLULAR MODIFICATIONS | DISCOVERX, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| EP-1474526-A4 | ENZYME ACTIVATION PROTEASE ASSAY | DISCOVERX INC (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1551965-A2 | SHORT ENZYME DONOR FRAGMENT | Discoverx, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1474526-A2 | ENZYME ACTIVATION PROTEASE ASSAY | Discoverx, Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040137480-A1 | Monitoring intracellular proteins | DISCOVERX, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20030219848-A1 | Short enzyme donor fragment | EUROFINS DISCOVERX CORPORATION | 2003-11-27 | — | — | US | disclosed |
| WO-2003093786-A2 | SHORT ENZYME DONOR FRAGMENT | DISCOVERX, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030170770-A1 | Enzyme activation protease assay | EUROFINS DISCOVERX CORPORATION | 2003-09-11 | — | — | US | disclosed |
| WO-2003065004-A2 | ENZYME ACTIVATION PROTEASE ASSAY | DISCOVERX, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030092070-A1 | Genetic construct intracellular monitoring system | EUROFINS DISCOVERX CORPORATION | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219848-A1 | Short enzyme donor fragment | GLB1, GBA3, GLA | SLC5A2 2571/4885EPHX2 3782/4885PYGL 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.